pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.

Vaccines 97

Vaccines Immunization 97

The Checkup by Singlecare

NOVEMBER 30, 2023

Acetaminophen may also blunt the effects of other medications that impact the immune system, including some medicines used to manage cancer diagnoses and even the immune response following vaccinations. However, after vaccine administration, ACIP recommends use for fever treatment and local pain.

Immunization 98

Immunization Vaccines FDA Labelling 98

pharmaphorum

DECEMBER 14, 2021

In COVID-19, the drug was being tested in patients with acute respiratory distress (ARDS), which like GvHD is caused by over-stimulation of inflammatory cytokines, which causes the immune system to attack the patient’s own body. It has made cumulative loses of almost $650 million since being founded in 2004.

Immunization 101

Immunization Vaccines FDA 101

The Checkup by Singlecare

OCTOBER 1, 2024

In 2004, after nearly eight decades, the American Pharmacists Association (APhA) expanded that week into a month, and October has been coined American Pharmacists Month ever since. This celebration has been a yearly tradition since 1925 , when radio stations would broadcast special programming to highlight the role of pharmacists.

Patient Care 52

Patient Care Immunization Vaccines 52

PharmaShots

FEBRUARY 21, 2023

Market Cap: $8.46M Founded Year: 2004 Total Employees: ~4 Headquarters: Texas, United States Stock Exchange: OTCMKTS QSam Biosciences is a clinical-stage biotech company focused on developing and commercializing targeted therapeutic radiopharmaceutical products for treating cancer and related diseases.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

PharmaShots

APRIL 25, 2023

Through its internal development, partnerships, and acquisitions, the company has put together four technology platforms that primarily focus on antibodies, T cells, innate immunity, and siRNAs. R&D Expenditure: $7.19B Founded Year: 2004 Total Employees: ~91,573,440 Headquarters: Paris, France Market Cap: $143.9B

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40